Premium
Surgical results of 40 patients with malignant tracheobronchial lesions
Author(s) -
WU MingHo,
TSENG YauLin,
LIN MuYen,
LAI WoWei
Publication year - 1997
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/j.1440-1843.1997.tb00086.x
Subject(s) - medicine , surgery , bronchopleural fistula , lung cancer , pneumonectomy , carcinoma , thyroid cancer , survival rate , mortality rate , cancer , empyema
The objective of this study was to evaluate the results of tracheobronchoplasty performed on a variety of malignant diseases which involved the tracheobronchus. Between July 1988 and March 1996 tracheobronchial surgery was performed on 40 patients who had a variety of malignant diseases. The primary diseases were bronchogenic carcinoma ( n = 26), tracheobronchial tumour ( n = 5), thyroid cancer ( n = 6), and oesophageal cancer ( n = 3). Operative procedures that were performed on the tracheobronchus were sleeve lobectomy ( n = 22) or bilobectomies ( n = 5), sleeve pneumonectomy ( n = 3), sleeve resection of trachea ( n = 7) and bronchus ( n = 3). There was one postoperative death with a mortality rate of 2.5%. However, there were no significant postoperative complications apart from the one postoperative death; one patient developed a bronchopleural fistula and empyema. In lung cancer patients, the 2 year survival rate was 47.3%, and one (3.8%) local tumour recurrence. Four of five patients who had tracheobronchial tumours were alive and free from disease during 2–6 year follow‐up period. One patient who had malignant fibrous histiocytoma died of brain metastasis 6 months after the operation. Among six patients whose thyroid cancer involved the trachea, one patient survived for 7 years, the other five patients were still alive and free from disease 2–5 years after the operation. Of the three patients whose oesophageal carcinoma involved the tracheobronchus, there was one operative death and the others died of tumour recurrence 1 and 2 years, respectively. We suggest that tracheobronchoplasty is a safe procedure with low morbidity and mortality rates in carefully selected patients with malignant diseases.